VRDN Holds Stage 2 Uptrend within Deep 60.6% Base below 33.78 Pivot

VRDN stock profile infographic with daily candles, 20, 50 and 150-day simple moving averages and volume, Stage 2 (Advancing), as of November 17, 2026 at 12:40 - CANSLIM Research
VRDN is trading at 29.80 and holding above a rising 30-week moving average, keeping its Stage 2 advancing structure intact even as it sits roughly 11.8% below its 52-week high. The market focus is on a deep 42-week base with a 60.6% depth and a 33.78 pivot, a faulty formation carrying an elevated failure rate, while a recent 71.5% run and a shallow 4.6% pullback have some traders watching for bull-flag continuation. Sentiment is constructive but unconfirmed, with no VCP contraction or volume dry-up yet to validate a breakout.

VRDN   Daily · data to 2026-11-16 close · 20 SMA 50 SMA 150 SMA
Frozen at publication – this chart does not move. Open live chart on TradingView →

SECTORHealthcareINDUSTRYBiotechnologyStage 2Weinstein stage
Data to US close: Mon 16 Nov 16:00 ET = Tue 17 Nov 05:00 HKTCreated: Tue 17 Nov 12:40 HKT = 23:40 ET

Inside the Full Report

  • 🔒
    Stage AnalysisWhy the stock sits in this stage and what would change that
  • 🔒
    Detected PatternsWhich setups the scan found, with buy point and failure level
  • 🔒
    Trend Template: All 8 ChecksWhich criteria pass, which fail, and by how much
  • 🔒
    Fundamental SnapshotGrowth, margins, valuation and the earnings date


Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Figures come from the scanned result (as of November 17, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.